Bionano Genomics, Inc. (BNGO) vs TScan Therapeutics, Inc. (TCRX)
A side-by-side comparison of Bionano Genomics, Inc. and TScan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BNGO
Bionano Genomics, Inc.
$1.45HealthcareDelayed quote: Oct 6, 2026, 3:39 PM EDT
TCRX
TScan Therapeutics, Inc.
$0.27HealthcareDelayed quote: Oct 6, 2026, 3:33 PM EDT
Total return — BNGO vs TCRX
growth of $100 · dividends reinvested · last 5yBNGO -100.0% (-78.9%/yr)TCRX -97.2% (-51.0%/yr)TCRX compounded faster over this window
Log scale — wide-divergence pair
BNGO TCRX
BNGO vs TCRX: by the numbers
- •BNGO is the larger company ($17M vs $17M market cap).
- •Both run net losses; BNGO's is the smaller (-106.58% vs -1655.35% net margin).
- •BNGO grew revenue faster over the past five years (17.97% vs 3.60% CAGR).
Metrics side by side
Valuation
| Metric | BNGO | TCRX |
|---|---|---|
| P/S ratio | 0.55 | 2.33 |
| P/B ratio | 0.52 | 0.24 |
Profitability
| Metric | BNGO | TCRX |
|---|---|---|
| Gross margin | 21.95% | 72.24% |
| Operating margin | -116.95% | -1315.38% |
| Net margin | -106.58% | -1655.35% |
| ROE | -101.76% | -170.55% |
| ROIC | -85.72% | -79.20% |
Growth (annualized)
| Metric | BNGO | TCRX |
|---|---|---|
| Revenue CAGR (5Y) | 17.97% | 3.60% |
| Total return CAGR (5Y) | -78.37% | -48.85% |
Frequently asked
- Which has grown faster, BNGO or TCRX?
- Over the past five years, BNGO grew revenue faster — BNGO at a 17.97% CAGR versus TCRX at 3.60%.
- How have BNGO and TCRX total returns compared?
- Over the past 5 years, BNGO delivered -78.37% and TCRX delivered -48.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bionano Genomics ROETScan Therapeutics ROEBionano Genomics operating marginTScan Therapeutics operating marginBionano Genomics revenue growthTScan Therapeutics revenue growthBionano Genomics free cash flowTScan Therapeutics free cash flow
Bionano Genomics & TScan Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.